Undecimal Bio
PrivateLast Round
Seed
Oct 13, 2026
Total Funding Raised
$18M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Undecimal Bio is a biotechnology company that develops an AI-enabled platform for the targeted delivery of siRNA therapeutics to specific cell types beyond the liver.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Undecimal Bio Comparables
Compare Undecimal Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Sixfold Bioscience | 85% | |
| Soufflé Therapeutics | 80% | |
| Rigerna Therapeutics | 78% |
Undecimal Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Oct 13, 2026 |
Undecimal Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Saras Capital | Seed |
| Verve Ventures | Seed |
| Entrée Capital | Seed |
| 4BIO Capital | Seed |
| IQ Capital | Seed |
| Harel Insurance Investments & Financial Services | Seed |
| Kerna Ventures | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 13, 2026
$18M round led by IQ Capital and 4BIO Capital.
Recent news
Latest coverage and updates
- is_developingOct 13, 2026
Undecimal Bio develops delivery molecules that carry gene-silencing medicines beyond the liver in the United Kingdom and Israel on Oct 13th '26
- receives_financingOct 13, 2026
Undecimal receives an oversubscribed $18M Seed financing round on Oct 13th '26 in the United Kingdom and Israel, co-led by 4BIO Capital and IQ Capital with participation from Verve Ventures, Harel Tech, Entree Capital, Kerna Ventures and Saras Capital, to expand its DELiveri platform for siRNA delivery beyond the liver.
Undecimal Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Undecimal Bio's valuation, stock price, and market status.
Is Undecimal Bio a public or private company?
Undecimal Bio is a private company.
What is the current stock price of Undecimal Bio?
Undecimal Bio is a private company, so its shares have no public market price. Caplight tracks Undecimal Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Undecimal Bio worth (valuation)?
Valuation information for Undecimal Bio is not publicly available.
Can I buy Undecimal Bio stock?
Undecimal Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Undecimal Bio's last funding round?
Undecimal Bio's most recent funding round was Seed on October 13, 2026.
Who are the main investors in Undecimal Bio?
Key investors in Undecimal Bio include 4BIO Capital, IQ Capital.
Will Undecimal Bio IPO soon?
No public IPO plans have been announced for Undecimal Bio.
How can I track Undecimal Bio secondary market activity?
Caplight tracks bids, offers, and trades in Undecimal Bio's shares on secondary markets.